Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Midwifery | 6 | 2022 | 32 | 1.450 |
Why?
|
| Smoking | 5 | 2020 | 866 | 0.820 |
Why?
|
| Models, Educational | 2 | 2019 | 67 | 0.670 |
Why?
|
| Obstetrics | 5 | 2020 | 85 | 0.650 |
Why?
|
| Smoking Cessation | 4 | 2020 | 550 | 0.550 |
Why?
|
| Tobacco Use Disorder | 2 | 2017 | 246 | 0.540 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 317 | 0.540 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2017 | 71 | 0.490 |
Why?
|
| Taste Perception | 1 | 2015 | 2 | 0.470 |
Why?
|
| Menthol | 1 | 2015 | 6 | 0.470 |
Why?
|
| Consumer Behavior | 1 | 2015 | 37 | 0.460 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 120 | 0.450 |
Why?
|
| Tobacco Products | 1 | 2015 | 80 | 0.440 |
Why?
|
| Gynecology | 3 | 2022 | 54 | 0.390 |
Why?
|
| Pregnancy | 13 | 2022 | 2337 | 0.380 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 733 | 0.320 |
Why?
|
| Internship and Residency | 3 | 2011 | 805 | 0.300 |
Why?
|
| Nurse Midwives | 2 | 2020 | 11 | 0.280 |
Why?
|
| Teaching | 1 | 2008 | 159 | 0.270 |
Why?
|
| Patient Care Team | 2 | 2015 | 338 | 0.260 |
Why?
|
| Nicotine | 3 | 2020 | 117 | 0.260 |
Why?
|
| Community-Institutional Relations | 1 | 2003 | 38 | 0.210 |
Why?
|
| Abortion, Induced | 1 | 2003 | 27 | 0.200 |
Why?
|
| Contraception | 1 | 2003 | 71 | 0.200 |
Why?
|
| Interprofessional Relations | 2 | 2022 | 134 | 0.190 |
Why?
|
| Smokers | 2 | 2020 | 119 | 0.190 |
Why?
|
| Curriculum | 3 | 2020 | 598 | 0.180 |
Why?
|
| Hospitals | 1 | 2003 | 393 | 0.170 |
Why?
|
| Education, Nursing | 1 | 2019 | 40 | 0.150 |
Why?
|
| Accreditation | 1 | 2019 | 78 | 0.150 |
Why?
|
| Female | 16 | 2022 | 32887 | 0.150 |
Why?
|
| Adult | 9 | 2020 | 16825 | 0.140 |
Why?
|
| Massachusetts | 3 | 2019 | 2076 | 0.140 |
Why?
|
| Premature Birth | 1 | 2019 | 112 | 0.140 |
Why?
|
| Humans | 18 | 2022 | 63463 | 0.130 |
Why?
|
| Maternal Health Services | 2 | 2020 | 66 | 0.120 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2015 | 19 | 0.120 |
Why?
|
| Research | 1 | 2017 | 193 | 0.120 |
Why?
|
| Professional Role | 1 | 2015 | 43 | 0.120 |
Why?
|
| Labor, Obstetric | 1 | 2015 | 37 | 0.120 |
Why?
|
| Taste | 1 | 2015 | 36 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 536 | 0.110 |
Why?
|
| Haplotypes | 1 | 2015 | 131 | 0.110 |
Why?
|
| Nurse Practitioners | 1 | 2015 | 117 | 0.110 |
Why?
|
| Counseling | 2 | 2015 | 362 | 0.110 |
Why?
|
| Biomarkers | 1 | 2020 | 1408 | 0.110 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 127 | 0.110 |
Why?
|
| Weight Gain | 1 | 2015 | 169 | 0.110 |
Why?
|
| Prenatal Care | 1 | 2015 | 170 | 0.100 |
Why?
|
| Young Adult | 3 | 2020 | 4695 | 0.100 |
Why?
|
| Genotype | 1 | 2015 | 665 | 0.100 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 507 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 491 | 0.100 |
Why?
|
| Pregnancy Complications | 2 | 2015 | 377 | 0.090 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2011 | 10 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 419 | 0.090 |
Why?
|
| Hemangioma | 1 | 1991 | 28 | 0.090 |
Why?
|
| Physician-Nurse Relations | 1 | 2011 | 26 | 0.090 |
Why?
|
| Laser Therapy | 1 | 1991 | 42 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1991 | 141 | 0.080 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 255 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 762 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2679 | 0.080 |
Why?
|
| Chewing Gum | 1 | 2008 | 9 | 0.070 |
Why?
|
| Nicotinic Agonists | 1 | 2008 | 39 | 0.070 |
Why?
|
| Nursing Evaluation Research | 1 | 2008 | 40 | 0.070 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2013 | 397 | 0.070 |
Why?
|
| Pregnancy Outcome | 2 | 2008 | 194 | 0.070 |
Why?
|
| Obesity | 1 | 2015 | 1234 | 0.070 |
Why?
|
| Abortion, Therapeutic | 1 | 2005 | 1 | 0.060 |
Why?
|
| Students, Medical | 1 | 2008 | 261 | 0.060 |
Why?
|
| Trichomonas Vaginitis | 1 | 2005 | 7 | 0.060 |
Why?
|
| Trichomonas vaginalis | 1 | 2005 | 9 | 0.060 |
Why?
|
| Mifepristone | 1 | 2005 | 19 | 0.060 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2005 | 25 | 0.060 |
Why?
|
| Misoprostol | 1 | 2005 | 9 | 0.060 |
Why?
|
| Vagina | 1 | 2005 | 83 | 0.060 |
Why?
|
| Family Planning Services | 1 | 2003 | 21 | 0.050 |
Why?
|
| Students | 1 | 2022 | 217 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2019 | 36 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1122 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2015 | 19 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 571 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 727 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 1359 | 0.030 |
Why?
|
| Infant | 1 | 2019 | 1650 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2015 | 198 | 0.030 |
Why?
|
| Vulvar Diseases | 1 | 1993 | 5 | 0.030 |
Why?
|
| Choristoma | 1 | 1993 | 22 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1993 | 46 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 514 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 777 | 0.020 |
Why?
|
| Breast | 1 | 1993 | 183 | 0.020 |
Why?
|
| Infertility, Female | 1 | 1991 | 46 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 866 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2011 | 93 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2015 | 689 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 6251 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 222 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2008 | 3297 | 0.020 |
Why?
|
| Cotinine | 1 | 2008 | 19 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1380 | 0.020 |
Why?
|
| Birth Weight | 1 | 2008 | 85 | 0.020 |
Why?
|
| Male | 1 | 2008 | 29905 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7844 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 739 | 0.020 |
Why?
|
| Dilatation and Curettage | 1 | 2005 | 3 | 0.010 |
Why?
|
| Chromatography | 1 | 2005 | 16 | 0.010 |
Why?
|
| Maternal Age | 1 | 2005 | 33 | 0.010 |
Why?
|
| Immunoassay | 1 | 2005 | 70 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2005 | 144 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 170 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1993 | 1198 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2005 | 62 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 298 | 0.010 |
Why?
|
| Gestational Age | 1 | 2005 | 189 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 373 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 369 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 863 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1148 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 1094 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1277 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 2469 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2005 | 2087 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 3777 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 5682 | 0.010 |
Why?
|
| Carcinoma, Skin Appendage | 1 | 1993 | 1 | 0.010 |
Why?
|
| Vulvar Neoplasms | 1 | 1993 | 11 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1993 | 978 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 17607 | 0.000 |
Why?
|
| Animals | 1 | 2005 | 20658 | 0.000 |
Why?
|
| Aged | 1 | 1993 | 14442 | 0.000 |
Why?
|